Highly sensitive to weight changes; scores typically improve by 13.5 to 16.6 points following clinically meaningful weight loss.
: Once licensed, users can access a print-ready PDF for paper-based implementation or utilize digital eCOA (electronic Clinical Outcome Assessment) versions. Clinical Significance iwqol-lite-ct pdf
The is more than just a document; it is a diagnostic window into the lived experience of obesity. For pharmaceutical companies testing GLP-1 agonists (like semaglutide or tirzepatide) or for bariatric surgery clinics, this PDF provides the data needed to prove that weight loss translates into actual life improvement. Highly sensitive to weight changes; scores typically improve
The instrument consists of divided into three main composite scores: It focuses on the most "responsive" elements of
The IWQoL-Lite-CT (Impact of Weight on Quality of Life–Lite Clinical Trials version) is a brief patient-reported outcome measure assessing weight-related quality of life across core domains used in clinical trials.
The "CT" version was developed to meet rigorous regulatory standards (such as those from the FDA) for assessing treatment efficacy in weight management studies. It focuses on the most "responsive" elements of quality of life—those most likely to change as a patient loses weight. Structure: It consists of (reduced from the original 31-item Lite version). Core Domains: The instrument assesses two primary composite scores: Physical Function:
